People · Operator
Named in public records as an officer, director or promoter · active 2009–2016 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| EXUMA Biotech Corp. | — | Biotechnology | Series C | $63.0M | $776.2M | 2016 |
| Femta Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $3.7M | $83.7M | 2009 |
Jay Short at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jay Short on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Frank McCormick | 1 | 7 |
| Scott Segal | 1 | 5 |
| Kenneth Widder | 1 | 2 |
| David Ramsay | 1 | 2 |
| Gregory Frost | 1 | 1 |
| Per Peterson | 1 | 1 |
| Jim Woody | 1 | 1 |
| Stephen Keane | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.